Orforglipron

Not a peptide. Orforglipron is a small-molecule (non-peptide) drug taken as a tablet. It activates the same GLP-1 receptor as semaglutide and the other peptide agonists, which is why it is constantly discussed alongside them and why people search for it here. The same evidence standards apply.

LY3502970, OWL833 (original Chugai code)

Metabolic & weight

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. Orforglipron has completed phase 3 trials and has been filed for approval for obesity in the US and elsewhere; its approval status at the time of reading should be checked †. Where approved, it is a prescription medicine, not a research compound.

Summary

Class: Oral non-peptide small-molecule GLP-1 receptor agonist (a biased/partial agonist that favours cyclic-AMP signalling over β-arrestin recruitment)
Mechanism: Activates the GLP-1 receptor from a once-daily tablet, producing glucose-dependent insulin release, lower glucagon, slower gastric emptying and reduced appetite, without needing a peptide to be absorbed
Routes studied: Oral once daily, taken without regard to food or water (unlike oral semaglutide)
Dose range reported: Phase 3: started at 1 mg daily, escalated every 4 weeks through 3 mg to maintenance doses of 3, 12 or 36 mg once daily. The approved dosing, where approved, follows this †
Half-life: Roughly 29–49 hours, supporting once-daily dosing †
Storage: Tablets: room temperature, dry, in original packaging
Regulatory status: Filed with FDA (obesity, 2025) with priority review; decision expected 2026 †; filings in other regions under way †

Doses are as reported in studies or by the community — never recommendations.

1What it is

Orforglipron is the first non-peptide GLP-1 receptor to complete phase 3 trials. Getting a small molecule to activate the GLP-1 receptor — a large receptor evolved to bind a 30-amino-acid hormone — took decades. The molecule was discovered by Chugai (Japan) and licensed to Eli Lilly in 2018. Because it is not a peptide, it is not destroyed in the stomach, does not need the absorption-enhancer and fasting rules of oral semaglutide (Rybelsus), and can be manufactured by conventional chemical synthesis at scale rather than by peptide synthesis or fermentation. Those three facts are why it is expected to change access to GLP-1 therapy.

Pharmacologically it is a "biased" agonist: it activates the receptor's cAMP pathway strongly but recruits β-arrestin weakly, which in theory reduces receptor desensitisation. Whether that translates into any clinical difference is unproven.

2How it's thought to work

Same downstream biology as the peptide GLP-1 (see semaglutide, profile 3):

Pancreas. glucose-dependent insulin release, glucagon suppression.

Stomach. slowed gastric emptying.

Brain. reduced appetite and food intake.

Pharmacokinetics. absorbed as a small molecule; daily dosing gives relatively steady exposure. Metabolised in the liver (CYP3A4 involvement †), which introduces drug-interaction considerations that peptide agonists lack.

A small molecule, not a peptide, that activates the same GLP-1 receptor. Because it is not digested, it can be swallowed without the absorption enhancer oral semaglutide needs.Schematic — not to scale

3What the research shows

Weight loss in adults with obesity without diabetes

ATTAIN-1 (n≈3,127, 72 weeks) reported mean weight change of about −7.5% (6 mg), −8.4% (12 mg) and −12.4% (36 mg) versus −0.9% with placebo (published 2025, NEJM †). Roughly 60% of participants on 36 mg lost ≥10%. This is somewhat less than injectable semaglutide 2.4 mg in STEP 1 (−14.9%) and well below tirzepatide, but it is a once-daily pill with no food restrictions.

Weight loss in adults with obesity and type 2 diabetes

ATTAIN-2 (72 weeks) reported about −10.5% at 36 mg versus −2.2% with placebo, with HbA1c reductions of about 1.3–1.8 percentage points †.

Glucose control in type 2 diabetes

ACHIEVE-1 (n=559, 40 weeks, drug-naive type 2 diabetes) reported HbA1c reductions of 1.3–1.6 percentage points versus −0.1 with placebo, and weight loss up to about 7.9% at 36 mg (Rosenstock 2025, NEJM). ACHIEVE-3 showed superiority to oral semaglutide on HbA1c and weight †; ACHIEVE-2 and -4 compared against dapagliflozin and insulin glargine respectively †. [3]

Phase 2

A 36-week phase 2 in obesity reported up to −14.7% weight loss at 45 mg (Wharton 2023, NEJM), and a phase 2 in type 2 diabetes reported HbA1c reductions up to −2.1 points (Frias 2023, Lancet). The 45 mg dose was not carried into phase 3. [1][2]

Not gradedpending

Cardiovascular outcomes

A cardiovascular outcome trial (ACHIEVE-4 includes a CV component †) has not yet reported. No claim of cardiovascular benefit can be made.

Graded A (one trial)

Weight maintenance after injectables

ATTAIN-MAINTAIN tested switching from injectable GLP-1 therapy to orforglipron to hold weight; results reported 2025 suggested orforglipron largely maintained weight versus regain on placebo †.

4Reported side effects and interactions

Literature-reported

Literature (common). nausea, vomiting, diarrhoea, constipation, dyspepsia and decreased appetite — mostly mild to moderate and during escalation, at rates broadly similar to injectable GLP-1 . Discontinuation for adverse events in ATTAIN-1 was roughly 5–10% depending on dose versus ~3% placebo †.

Serious / warnings. class GLP-1 cautions apply — pancreatitis, gallbladder disease, hypoglycaemia with insulin or sulfonylureas, delayed gastric emptying and anaesthesia aspiration risk, kidney injury from dehydration. Small increases in heart rate. The rodent thyroid C-cell concern is specific to long-acting peptide agonists and whether it is carried on the orforglipron label should be checked †. A small number of liver enzyme elevations were reported in trials †. Not for pregnancy.

Community-reported

limited so far; tablets have not circulated widely outside trials. Any "orforglipron" sold as a research chemical is of unknown identity and purity.

Interactions. unlike peptide agonists, orforglipron is metabolised by liver enzymes and the label (where approved) is expected to carry interaction advice for strong CYP3A4 inhibitors/inducers †; slowed gastric emptying affects oral drug absorption; hypoglycaemia with insulin and sulfonylureas; oral contraceptive absorption should be checked against the final label.

Markers researchers commonly monitor

Following the trial protocols and GLP-1 class practice:

Marker	Why it's watched
HbA1c and fasting glucose	primary glycaemic measure; hypoglycaemia screening with insulin or sulfonylureas.
Liver enzymes (ALT/AST)	as a liver-metabolised small molecule with some enzyme elevations reported in trials, a baseline and periodic check is sensible †.
eGFR and creatinine	dehydration from GI effects.
Lipid panel and blood pressure	improved in trials.
Heart rate	small class-typical increase.
Body composition and grip strength	lean-mass loss accompanies GLP-1-driven weight loss; untested specifically for orforglipron.
Medication review for CYP3A4 interactions	not a lab test, but the one monitoring step that differs from peptide agonists.

Free for everyone. Safety information is never behind a paywall.

5Formulation and handling

Once-daily tablet, taken at any time of day with or without food or water — the practical advantage over oral semaglutide, which must be taken fasting with a small amount of water and a 30-minute wait. Store at room temperature. Dose escalation every 4 weeks is how GI effects were kept manageable in trials. Tablets should not be split; there is no and the calculator does not apply.

6Commonly studied alongside

Metformin and other oral diabetes drugs (ACHIEVE programme); compared against oral semaglutide, dapagliflozin and insulin glargine. Studied as a maintenance therapy after injectable semaglutide or tirzepatide. Related oral GLP-1 small molecules in development: danuglipron (Pfizer, discontinued 2025), various Chinese candidates †.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	New drug application for obesity submitted 2025 with a priority review voucher; FDA decision expected in 2026 †. Type 2 diabetes filing to follow †
European Union	Filing status †
United Kingdom	Filing status †
Australia	Not yet approved †
South Africa	Not registered †
Sport	Not prohibited by WADA (GLP-1 agonists not listed as of 2026 †)

8Open questions

Cardiovascular outcomes — unknown until the outcome trial reports.
Whether biased agonism translates to any difference in durability or side effects.
Weight regain after stopping, and performance as a maintenance drug after injectables over the long term.
Real-world drug–drug interactions and liver safety at scale.

9References

1Wharton S et al. (2023). Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. NEJM. PubMed · DOI
2Frias JP et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. PubMed · DOI
3Rosenstock J et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). NEJM. PubMed · DOI
4ATTAIN-1 investigators (2025). Orforglipron in adults with obesity without diabetes: a 72-week phase 3 trial. NEJM [verify authors and title]. PubMed
5ATTAIN-2 investigators (2025). Orforglipron in adults with obesity and type 2 diabetes. [verify journal]. PubMed
6Kawai T et al. (2020). Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci USA. PubMed · DOI
7Eli Lilly (2025). Orforglipron regulatory submission announcements [verify]. PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.